Literature DB >> 3121360

Anti-interferon-gamma antibody protects mice against the generalized Shwartzman reaction.

A Billiau1, H Heremans, F Vandekerckhove, C Dillen.   

Abstract

A generalized Shwartzman reaction was found to occur in non-SPF-NMRI mice given a local injection of S. marcescens lipopolysaccharide (LPS) in the footpad, followed, with an interval of 24 h, by an i.v. injection. The reaction occurred several hours after the second injection. It was characterized by disseminated subcutaneous bleedings at the mouth, anus, conjuctiva, nose tip and tail end. Most mice died within 24-48 h. The size of the LPS dose given in the footpad (5 micrograms) was found to be critical in that the reaction failed to occur with higher as well as lower doses. The reaction was found to be completely absent in mice that had received one or more systemic injections of monoclonal antibodies with neutralizing potential for murine interferon-gamma (IFN-gamma). Mice treated with control preparations, including a monoclonal antibody with binding but no neutralizing activity for murine IFN-gamma, remained sensitive to induction of the reaction. These observations assign a crucial role to endogenous IFN-gamma in the elicitation of the generalized Shwartzman reaction and open perspectives for the prevention or therapy of clinical conditions related to the Shwartzman reaction by the use of antibodies to IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121360     DOI: 10.1002/eji.1830171228

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

Review 1.  Immune therapy in sepsis: Are we ready to try again?

Authors:  Roger Davies; Kieran O'Dea; Anthony Gordon
Journal:  J Intensive Care Soc       Date:  2018-04-04

2.  Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody.

Authors:  I Wiesenberg; P H Van der Meide; H Schellekens; S Alkan
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  The role of interferon-γ in the pathogenesis of acute intra-abdominal sepsis.

Authors:  Christopher R Romero; Daniela S Herzig; Anthony Etogo; Jesus Nunez; Rod Mahmoudizad; Geping Fang; E D Murphey; Tracy Toliver-Kinsky; Edward R Sherwood
Journal:  J Leukoc Biol       Date:  2010-07-13       Impact factor: 4.962

Review 4.  Interaction of interferon with other cytokines.

Authors:  G Opdenakker; Y Cabeza-Arvelaiz; J Van Damme
Journal:  Experientia       Date:  1989-06-15

5.  Recombinant gamma interferon causes neutrophil migration mediated by the release of a macrophage neutrophil chemotactic factor.

Authors:  R A Ribeiro; F Q Cunha; S H Ferreira
Journal:  Int J Exp Pathol       Date:  1990-10       Impact factor: 1.925

6.  Selective modulation of lipopolysaccharide-induced death and cytokine production by various muramyl peptides.

Authors:  M A Parant; P Pouillart; C Le Contel; F J Parant; L A Chedid; G M Bahr
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Gamma interferon prevents the inhibitory effects of oxidative stress on host responses to Escherichia coli infection.

Authors:  M J Parmely; F Wang; D Wright
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Interferon-gamma and polyunsaturated fatty acids increase the binding of lipopolysaccharide to macrophages.

Authors:  H Darmani; J Parton; J L Harwood; S K Jackson
Journal:  Int J Exp Pathol       Date:  1994-10       Impact factor: 1.925

9.  Aminoglycosides modify the in vitro metachromatic reaction and murine generalized Shwartzman phenomenon induced by Salmonella minnesota R595 lipopolysaccharide.

Authors:  A Focà; G Matera; D Iannello; M C Berlinghieri; M C Liberto
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

10.  Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon.

Authors:  F P Heinzel; R M Rerko; P Ling; J Hakimi; D S Schoenhaut
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.